CLINICAL TRIAL: RAGE

$16,434M01FY2009RRNIH

Howard University, Washington DC

Investigators

Linked publications & trials

Paper 38190104 Paper 37273492 Paper 35642061 Paper 33729508 Paper 33075101 Paper 32697331 Paper 32372009 Paper 32243618 Paper 32211507 Paper 31764101 Paper 31115244 Paper 30698716 Paper 30325721 Paper 29769661 Paper 29454196 Paper 29377283 Paper 29203084 Paper 28726810 Paper 28234671 Paper 28012682 Paper 27656434 Paper 27618452 Paper 27526315 Paper 27321945 Paper 27196697 Paper 27177148 Paper 26896107 Paper 26810768 Paper 26691066 Paper 26686224 Paper 26571023 Paper 26025194 Paper 25942459 Paper 25785798 Paper 25642295 Paper 25134052 Paper 25102180 Paper 25042611 Paper 24926856 Paper 24893885 Paper 24650816 Paper 24603370 Paper 24585758 Paper 24361300 Paper 24296284 Paper 24028863 Paper 23993337 Paper 23966867 Paper 23915245 Paper 23862295 Paper 23842951 Paper 23583978 Paper 23560516 Paper 23416278 Paper 23406172 Paper 23293696 Paper 23123367 Paper 23065513 Paper 23028791 Paper 22983573 Paper 22973513 Paper 22954966 Paper 22936743 Paper 22870570 Paper 22837643 Paper 22830455 Paper 22791750 Paper 22768081 Paper 22761678 Paper 22720276 Paper 22563607 Paper 22492993 Paper 22488930 Paper 22428356 Paper 22428342 Paper 22235947 Paper 22216000 Paper 22205395 Paper 22191677 Paper 22085899 Paper 21999035 Paper 21999034 Paper 21993671 Paper 21956416 Paper 21931561 Paper 21909115 Paper 21900080 Paper 21890147 Paper 21881522 Paper 21876117 Paper 21773025 Paper 21768215 Paper 21635713 Paper 21614697 Paper 21546502 Paper 21533037 Paper 21483845 Paper 21448230 Paper 21294900 Paper 21288821

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This Phase 2 study is a double-blind, placebo-controlled, randomized, multicenter study evaluating the efficacy and safety of 18 months of treatment sith PF-04494700. Participants radomized to 3 treatment groups will receive 20mg, 5mg and placebo capsules respectively. The study will recruit approximately 399 participants that are 50 years or older and diagnosed with mild to moderate AD as will be indicated from MMSE scores of 14-26. The Howard University site will recruit and monitor 15 of the 399 particpants in the study.

View original record on NIH RePORTER →